Ticker: PTCT

PTC Therapeutics

Biotech Healthcare Biotechnology
Price 56.42
Reco Sell Potential 30 Risk 80 Updated 2026-11-21

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

PTC Therapeutics is a biotechnology company focused on developing innovative therapies for rare diseases and genetic disorders. Its core products include treatments for Duchenne muscular dystrophy and other genetic conditions. The company operates primarily in the healthcare sector, with major revenue sources stemming from product sales and collaborations with other pharmaceutical companies.

Investment Profile

The investment profile of PTC Therapeutics is more aligned with growth investors, given its focus on innovative therapies and potential for future revenue increases. The stock may appeal to those looking for long-term capital appreciation rather than immediate income, as it does not currently offer dividends.

Fundamental metrics (experimental) Updated: 2026-11-22
EPS (TTM) — earnings per share for the last 12 months, $
-1.31
Revenue QoQ — quarter-over-quarter revenue growth
-0.8%
EPS surprise
-532.4%
20d volatility
3.6%
AI recommendation changes
Date Before After Reason
2026-10-09 — Sell Weak fundamentals and negative momentum raise significant concerns.
Analyst forecasts
Date Analyst Action Target Price Then
2026-10-20 Raymond James Target Lowered 108 → 106 62.905
2026-10-15 UBS Update — → 90 59.67
2026-10-08 RBC Capital Target Lowered 85 → 75 62.45
News Page 1 of 1
PTC Therapeutics Ultra Clean Holdings

Analysts BTIG suggest potential buying opportunity for small-cap stocks as Russell 2000 underperforms amid rising Treasury yields

The recent decline in small-cap stocks, particularly the Russell 2000, highlights the impact of rising Treasury yields, which have led investors to favor larger tech companies. Analysts suggest that this may present a potential buying opportunity for small-cap stocks if yields stabilize.